Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification
European Journal of Surgical Oncology · 2023
DOI: 10.1016/j.ejso.2023.04.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2023. Verfasst von A Floortje van Oosten und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands; Depart…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Living With Hope, Living With Hope Foundation, VSB Fonds.
Abstract (Originalsprache)
BACKGROUND: Over 80% of patients will develop disease recurrence after radical resection of pancreatic ductal adenocarcinoma (PDAC). This study aims to develop and validate a clinical risk score predicting post-recurrence survival (PRS) at time of recurrence. METHODS: All patients who had recurrence after undergoing pancreatectomy for PDAC at the Johns Hopkins Hospital or at the Regional Academic Cancer Center Utrecht during the study period were included. Cox proportional hazard model was used to develop the risk model. Performance of the final model was assessed in a test set after internal validation. RESULTS: Of 718 resected PDAC patients, 72% had recurrence after a median follow-up of 32 months. The median overall survival was 21 months and the median PRS was 9 months. Prognostic factors associated with shorter PRS were age (hazard ratio [HR] 1.02; 95% confidence interval [95%CI] 1.00-1.04), multiple-site recurrence (HR 1.57; 95%CI 1.08-2.28), and symptoms at time of recurrence (HR 2.33; 95%CI 1.59-3.41). Recurrence-free survival longer than 12 months (HR 0.55; 95%CI 0.36-0.83), FOLFIRINOX and gemcitabine-based adjuvant chemotherapy (HR 0.45; 95%CI 0.25-0.81; HR 0.58; 95%CI 0.26-0.93, respectively) were associated with a longer PRS. The resulting risk score had a good predictive accuracy (C-index: 0.73). CONCLUSION: This study developed a clinical risk score based on an international cohort that predicts PRS in patients who underwent surgical resection for PDAC. This risk score will become available on www.evidencio.com and can help clinicians with patient counseling on prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands; Department of Surgery, The Johns Hopkins University School of Medicine, Balt…
- Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands; Division of Imaging and Oncology, University Medical Center Utrecht Cancer C…
- Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands.
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Surgery, New York University Langone Medical Center, New York City, NY, USA.
- Department of Surgery, New York University Langone Medical Center, New York City, NY, USA.
Förderung
- Stichting Living With Hope
- Living With Hope Foundation
- VSB Fonds
Zitieren
APA
van Oosten, A. F., Daamen, L. A., Groot, V. P., Biesma, N. C., Habib, J. R., van Goor, I. W. J. M., Kinny-Köster, B., Burkhart, R. A., Wolfgang, C. L., van Santvoort, H. C., He, J., & Molenaar, I. Q. (2023). Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2023.04.009
Vancouver
van Oosten AF, Daamen LA, Groot VP, Biesma NC, Habib JR, van Goor IWJM, et al. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. European Journal of Surgical Oncology. 2023. doi:10.1016/j.ejso.2023.04.009
BibTeX
@article{vanOosten2023,
author = {van Oosten, A Floortje and Daamen, Lois A and Groot, Vincent P and Biesma, Nanske C and Habib, Joseph R and van Goor, Iris W J M and Kinny-Köster, Benedict and Burkhart, Richard A and Wolfgang, Christopher L and van Santvoort, Hjalmar C and He, Jin and Molenaar, I Quintus},
title = {Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification},
journal = {European Journal of Surgical Oncology},
year = {2023},
doi = {10.1016/j.ejso.2023.04.009}
}
EUVIMED